Phreesia Q2 revenue up 10% to $129.5 million

Phreesia posts 10% Q2 revenue growth, stronger profitability and free cash flow, trims debt by $23.5 million, and reiterates its fiscal 2027 revenue and Adjusted EBITDA outlook.

Rhea-AI Filing Summary

Phreesia, Inc. (PHR) reported fiscal second-quarter 2027 results for the period ended July 31, 2026, showing continued growth and improved profitability. Total revenue was $129.5 million, up 10% year-over-year, led by 36% growth in payment solutions, while network solutions grew 9% and subscription and related services declined 2% as the company moderates subscription pricing in favor of downstream revenues.

Net income was $1.9 million versus $0.7 million a year earlier, and Adjusted EBITDA rose to $32.9 million from $22.1 million, reflecting operating leverage as major operating expense lines declined year-over-year. Phreesia generated $18.3 million of operating cash flow and $13.8 million of free cash flow, which, together with available cash, supported a $23.5 million reduction in long-term debt during the quarter; long-term debt stood at about $60.7 million at quarter end.

The business base continued to expand: Average Healthcare Services Clients (AHSCs) reached 4,744, up 6% year-over-year, and revenue per AHSC was $27,289, up 4%. Management is maintaining its fiscal 2027 guidance for revenue of $510–$520 million and Adjusted EBITDA of $125–$135 million, which assumes roughly $37 million of revenue contribution from AccessOne. A restructuring plan announced in May 2026, eliminating about 220 positions with expected charges of roughly $10 million, is intended to lower operating expenses and drive run-rate savings.

Positive

• Revenue and profitability improved, with Q2 revenue up 10% year-over-year to $129.5 million, net income rising to $1.9 million from $0.7 million, and Adjusted EBITDA up to $32.9 million from $22.1 million.
• The company generated $18.3 million of operating cash flow and $13.8 million of free cash flow in Q2, enabling a $23.5 million reduction in long-term debt and ending the quarter with $74.6 million in cash, cash equivalents and restricted cash.
• Management reaffirmed fiscal 2027 guidance for revenue of $510–$520 million and Adjusted EBITDA of $125–$135 million, and expects mid-single-digit AHSC growth and low-single-digit revenue-per-AHSC growth.
• Payment solutions remain a growth engine, with 36% year-over-year revenue growth and Q2 total managed payments of $1.626 billion at a 2.4% payment solutions revenue rate.

Negative

• A May 2026 restructuring plan eliminates approximately 220 positions and is expected to incur about $10 million in restructuring charges, including $2.8 million recognized in Q2.
• The company notes increased variability in forecasting network solutions revenue in the second half of each fiscal year, adding uncertainty around that part of the business.
• Subscription and related services revenue declined 2% year-over-year in Q2 as the company moderates subscription pricing in favor of downstream revenue growth.

Filing Explained

The filing furnishes unaudited results; its payment metric combines transaction volume and receivables, so 2.4% is not a processing take rate.

Phreesia’s September 2 Form 8-K reports its fiscal second-quarter results and furnishes the accompanying press release and stakeholder letter under Item 2.02; those materials describe the quarter as unaudited.

The balance sheet lists $63.5 million of issued common shares at July 31, 2026, versus $62.0 million at January 31, 2026. If that change reflects newly issued shares, the supplied dilution definition says an existing holder’s percentage ownership would decline absent offsetting changes.

The filing explains that its new payment measures combine transaction activity with average outstanding cardholder receivables. Accordingly, the reported $1.626 billion of total managed payments and 2.4% payment solutions revenue rate should not be read as a processing take rate, interest yield, or margin.

Adjusted EBITDA and free cash flow remain non-GAAP measures: Adjusted EBITDA excludes items including stock compensation, interest, taxes, depreciation and amortization, while free cash flow subtracts capitalized software costs and property purchases from operating cash flow.

The filing says the information under Item 2.02 and the exhibits is furnished rather than filed for Section 18 purposes, and identifies the forthcoming Form 10-Q as the source for additional quarterly detail.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Q2 2027 Revenue: $129.5 million Q2 2027 Net Income: $1.9 million Q2 2027 Adjusted EBITDA: $32.9 million +5 more

8 metrics

Q2 2027 Revenue $129.5 million Fiscal second quarter ended July 31, 2026; 10% year-over-year growth

Q2 2027 Net Income $1.9 million Quarter ended July 31, 2026, up from $0.7 million a year earlier

Q2 2027 Adjusted EBITDA $32.9 million Quarter ended July 31, 2026, compared with $22.1 million in prior-year quarter

Operating Cash Flow $18.3 million Net cash provided by operating activities in Q2 2027 vs $14.8 million in Q2 2026

Free Cash Flow $13.8 million Fiscal Q2 2027 free cash flow vs $9.6 million in the prior-year quarter

Fiscal 2027 Revenue Guidance $510–$520 million Management’s maintained outlook for the year ending January 31, 2027

Fiscal 2027 Adjusted EBITDA Guidance $125–$135 million Maintained full-year Adjusted EBITDA outlook

Total Managed Payments $1.626 billion Payment solutions total managed payments in Q2 2027 with 2.4% revenue rate

Key Terms

Adjusted EBITDA, free cash flow, Average Healthcare Services Clients, total managed payments, +2 more

6 terms

Adjusted EBITDA financial

"Adjusted EBITDA was $32.9 million in the quarter, as compared to $22.1 million"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

free cash flow financial

"Free cash flow was $13.8 million in the quarter, as compared to $9.6 million"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

Average Healthcare Services Clients financial

"Average number of healthcare services clients ("AHSCs") was 4,744 in the quarter"

total managed payments financial

"In the second quarter of fiscal 2027, our total managed payments were $1.626 billion"

payment solutions revenue rate financial

"our payment solutions revenue rate was 2.4%"

restructuring plan financial

"we implemented a restructuring plan (the “Plan”) intended to reduce operating expenses"

A restructuring plan is a company’s roadmap for reorganizing its operations, debts, or assets to improve financial health and efficiency; think of it as rewriting a household budget and chores when income changes. Investors care because the plan can affect a company’s ability to repay loans, generate profits, and sustain growth—successful restructuring can restore value, while a poorly executed one can signal continued trouble or reduced returns.

Earnings Snapshot

Revenue: $129.5 million · Guidance included

Fiscal second quarter 2027 (three months ended July 31, 2026)

Revenue $129.5 million Up 10% year-over-year

Net income $1.9 million Increased from $0.7 million in prior-year quarter

Adjusted EBITDA $32.9 million Increased from $22.1 million in prior-year quarter

Operating cash flow $18.3 million Increased from $14.8 million in prior-year quarter

Free cash flow $13.8 million Increased from $9.6 million in prior-year quarter

Guidance

For fiscal 2027, the company expects revenue of $510–$520 million and Adjusted EBITDA of $125–$135 million, with mid-single-digit AHSC growth and low-single-digit growth in total revenue per AHSC.

FAQ

How did Phreesia (PHR) perform financially in its fiscal Q2 2027?

Phreesia reported Q2 revenue of $129.5 million, up 10% year-over-year, driven by 36% growth in payment solutions. Net income was $1.9 million versus $0.7 million a year earlier, and Adjusted EBITDA increased to $32.9 million from $22.1 million.

What cash flow and debt metrics did Phreesia (PHR) report for Q2 2027?

In fiscal Q2 2027, Phreesia generated $18.3 million in operating cash flow and $13.8 million in free cash flow. It used cash to reduce long-term debt by $23.5 million, ending July 31, 2026 with $60.7 million of long-term debt and $74.6 million in cash, cash equivalents and restricted cash.

What guidance did Phreesia (PHR) provide for fiscal 2027?

Phreesia expects fiscal 2027 revenue of $510–$520 million and Adjusted EBITDA of $125–$135 million. The outlook assumes around $37 million of revenue from AccessOne and mid-single-digit AHSC growth with low-single-digit growth in total revenue per AHSC.

How are Phreesia’s key client metrics trending in Q2 2027?

Average Healthcare Services Clients (AHSCs) were 4,744 in Q2, up 6% year-over-year. Total revenue per AHSC was $27,289, a 4% year-over-year increase, though it declined about 2% sequentially due to seasonal payment processing patterns and continued client growth.

What is Phreesia’s restructuring plan and its financial impact?

On May 7, 2026 Phreesia implemented a restructuring plan eliminating about 220 positions, roughly half contractor roles. It expects approximately $10 million in total restructuring charges, primarily severance and related costs, with $2.8 million recorded in Q2 and anticipated annualized expense savings.

How significant is the AccessOne acquisition to Phreesia’s outlook?

AccessOne is a major driver of payment solutions growth. Phreesia’s fiscal 2027 outlook assumes about $37 million of revenue contribution from AccessOne. Management highlights AccessOne, along with ProviderConnect, as important products for future growth.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:06 PM Accepted by SEC EDGAR 09/02/2026 - 04:05 PM Learn about SEC filing dates

false000141240800014124082026-09-022026-09-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported)

September 2, 2026

___________________________________

Phreesia, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation or organization) 001-38977 (Commission File Number) 20-2275479 (I.R.S. Employer Identification Number)

1521 Concord Pike, Suite 301 PMB 221

Wilmington, Delaware 19803

(Address of principal executive offices and zip code)

(888) 654-7473

(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.01 per share			PHR			The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 - Results of Operations and Financial Condition

On September 2, 2026, Phreesia, Inc. (the “Company”) announced its financial results for the fiscal second quarter ended July 31, 2026 by issuing a stakeholder letter (the "Letter") and a press release. Copies of the press release and the Letter are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

The information furnished under this Item 2.02 and in the accompanying Exhibit 99.1 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number						Description
99.1						Press release, dated September 2, 2026, by Phreesia, Inc.
99.2						Stakeholder letter, dated September 2, 2026, by Phreesia, Inc.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 2, 2026			Phreesia, Inc.
			By:			/s/ Balaji Gandhi
			Name:			Balaji Gandhi
			Title:			Chief Financial Officer

Exhibit 99.1

Phreesia Announces Second Quarter Fiscal 2027 Results

ALL-REMOTE COMPANY/WILMINGTON, Del., September 2, 2026 – Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2026.

“Phreesia delivered a solid fiscal second quarter, with revenue growth and profitability expansion in line with our expectations. We generated positive operating and free cash flow again this quarter, which together with available cash allowed us to reduce debt principal by over $23 million while maintaining a healthy cash balance,” said CEO and Co-Founder Chaim Indig. “We remain enthusiastic about two products that we believe will drive future growth, AccessOne and ProviderConnect, as well as the impact that our artificial intelligence (AI) investments are beginning to have on many aspects of our products and broader organization.”

Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal 2027 Stakeholder Letter.

Fiscal Second Quarter Ended July 31, 2026 Highlights

•Total revenue was $129.5 million in the quarter, up 10% year-over-year.

•Average number of healthcare services clients ("AHSCs") was 4,744 in the quarter, up 6% year-over-year.

•Total revenue per AHSC was $27,289 in the quarter, up 4% year-over-year. See "Key Metrics" below for additional information.

•Net income was $1.9 million in the quarter, as compared to net income of $0.7 million in the same period in the prior year.

•Adjusted EBITDA1 was $32.9 million in the quarter, as compared to $22.1 million in the same period in the prior year.

•Net cash provided by operating activities was $18.3 million in the quarter, as compared to $14.8 million in the same period in the prior year.

•Free cash flow2 was $13.8 million in the quarter, as compared to $9.6 million in the same period in the prior year.

•Cash, cash equivalents and restricted cash as of July 31, 2026 was $74.6 million, an increase of $0.8 million from January 31, 2026. As of July 31, 2026, cash, cash equivalents and restricted cash included $1.7 million of long-term restricted cash classified within other long-term assets.

Recent Developments

Restructuring Plan

On May 7, 2026, we implemented a restructuring plan (the “Plan”) intended to reduce operating expenses and better align the cost structure with our current business priorities. The Plan includes the elimination of approximately 220 positions, approximately half of which are contractor roles. We expect total restructuring charges in connection with the Plan to be approximately $10 million, substantially all of which are expected to consist of employee transition costs, severance payments and related employee benefits, and taxes. Restructuring charges of

1 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net income (loss) before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of Fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. See “Non-GAAP Financial Measures” for more information and a reconciliation of Adjusted EBITDA to the closest GAAP measure.

2 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See “Non-GAAP Financial Measures” for a reconciliation of free cash flow to the closest GAAP measure.

approximately $2.8 million were recognized for the Plan during the second quarter of fiscal 2027. We expect the Plan to be substantially completed during fiscal year 2027.

Fiscal 2027 Outlook

We are maintaining our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million. As we noted over the past several quarters, there is now more variability in our network solutions revenue forecasting, particularly in the second half of each fiscal year. Our visibility into revenue across the other parts of our business is generally consistent with our views in our March 2026 earnings disclosure. The revenue range provided for fiscal 2027 assumes approximately $37 million of contribution from AccessOne (as defined below) and no additional revenue from potential future acquisitions completed between now and January 31, 2027.

We are maintaining our Adjusted EBITDA outlook for fiscal 2027. We expect Adjusted EBITDA to be in the range of $125 million to $135 million. As a reminder, in May 2026, we implemented a restructuring plan intended to reduce operating expenses and better align our cost structure with our current business priorities. The plan is expected to result in meaningful annualized run-rate expense savings, which were reflected in our Adjusted EBITDA outlook provided on March 30, 2026 and reaffirmed on May 27, 2026.

We are maintaining our expectation for AHSC growth in the mid-single-digit percentage range, and we are maintaining our outlook for total revenue per AHSC to grow in the low-single-digit percentage range in fiscal 2027.

We believe our cash, cash equivalents, restricted cash and cash generated in our normal operations will be sufficient to reach our fiscal 2027 outlook and meet our obligations for at least the next twelve months. As of July 31, 2026 we had $61 million in borrowings outstanding under our credit facility with Capital One.

Non-GAAP3 Financial Measures

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other expense (income), net and income tax expense (benefit), which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see “Non-GAAP Financial Measures” below.

Available Information

We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release includes express or implied statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, Adjusted EBITDA and cash flows; our expectations regarding demand for our solutions and visibility into future revenue; our expectations regarding our restructuring plan, including the anticipated amount, timing and composition of restructuring charges, reductions in operating expenses and resulting expense savings; the expected results of the acquisition of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, “AccessOne” and such acquisition, the “AccessOne Acquisition”) discussed herein, including anticipated additional revenue; our ability to meet our obligations for the next twelve months and achieve our fiscal 2027 outlook with our current cash, cash equivalents, restricted cash and cash generated in our normal operations; our outlook for fiscal 2027, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and total revenue per AHSC; our ability to continue generating positive net income and free cash flow; our business strategy and operating plans; the factors that drive our revenue growth; our growth expectations and strategies for the AccessOne business and ProviderConnect; our ability to offer the AccessOne solution to additional clients and access to capital; our

3 GAAP is defined as generally accepted accounting principles in the United States.

expectations regarding new solutions and solutions under development and the use of artificial intelligence in our solutions; and our expectations regarding the impacts of AI across our products and broader organization. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; the competitive environment in which we operate; our ability to comply with the covenants in our credit facility with Capital One and the securitization program with PNC Bank; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general, market, political, economic and business conditions (including from the U.S. federal government, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission (“SEC”), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above.

Conference Call Information

We will hold a conference call on Wednesday, September 2, 2026 at 5:00 p.m. Eastern Time to review our fiscal 2027 second quarter financial results. To participate in our live conference call and webcast, please dial (833) 461-5787 (or (626) 884-3620 for international participants) using conference code number 285419602 or visit the “Events & Presentations” section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Phreesia

Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025—1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and

more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

Investor Relations Contact:

Balaji Gandhi

Phreesia, Inc.

investors@phreesia.com

(929) 506-4950

Media Contact:

Nicole Gist

Phreesia, Inc.

nicole.gist@phreesia.com
(407) 760-6274

Phreesia, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share data)

			July 31, 2026						January 31, 2026
			(Unaudited)
Assets
Current:
Cash, cash equivalents and restricted cash (including restricted cash of $— and $1,691 as of July 31, 2026 and January 31, 2026, respectively)			$	72,945					$	73,830
Settlement assets			26,746						32,999
Accounts receivable, net of allowance for doubtful accounts of $879 and $1,523 as of July 31, 2026 and January 31, 2026, respectively			89,406						97,453
Cardholder receivables			29,351						38,330
Deferred purchase price receivables			14,799						18,003
Accrued interest and fees receivables			723						840
Deferred contract acquisition costs			394						410
Prepaid expenses and other current assets			19,139						17,978
Total current assets			253,503						279,843
Property and equipment, net of accumulated depreciation and amortization of $90,281 and $94,193 as of July 31, 2026 and January 31, 2026, respectively			18,122						20,332
Capitalized internal-use software, net of accumulated amortization of $77,389 and $69,390 as of July 31, 2026 and January 31, 2026, respectively			54,127						54,270
Operating lease right-of-use assets			1,205						2,002
Deferred contract acquisition costs			130						338
Intangible assets, net of accumulated amortization of $18,728 and $13,489 as of July 31, 2026 and January 31, 2026, respectively			74,522						79,761
Goodwill			171,468						170,064
Deferred tax assets			990						1,593
Other assets (includes $1,691 and $— of long-term restricted cash as of July 31, 2026 and January 31, 2026, respectively)			6,669						2,442
Long-term cardholder receivables			59,587						47,723
Long-term deferred purchase price receivables			6,654						5,422
Total Assets			$	646,977					$	663,790
Liabilities and Stockholders’ Equity
Current:
Settlement obligations			$	26,746					$	32,999
Current portion of debt and finance lease liabilities			5,281						7,971
Current portion of operating lease liabilities			824						1,254
Accounts payable			12,237						11,477
Accrued expenses			35,706						41,257
Due to healthcare providers			29,737						38,056
Deferred revenue			32,573						49,522
Other current liabilities			731						705
Total current liabilities			143,835						183,241
Long-term debt and finance lease liabilities			61,165						92,117
Operating lease liabilities, non-current			677						1,107
Long-term due to healthcare providers			59,734						45,329
Long-term deferred revenue			4,687						244
Long-term deferred tax liabilities			4,589						4,498
Other long-term liabilities			439						47
Total Liabilities			275,126						326,583
Commitments and contingencies
Stockholders’ Equity:
Preferred stock, undesignated, $0.01 par value—20,000,000 shares authorized as of both July 31, 2026 and January 31, 2026; no shares issued or outstanding as of both July 31, 2026 and January 31, 2026			—						—
Common stock, $0.01 par value—500,000,000 shares authorized as of both July 31, 2026 and January 31, 2026; 63,516,793 and 62,020,186 shares issued as of July 31, 2026 and January 31, 2026, respectively			635						620
Additional paid-in capital			1,212,775						1,181,679
Accumulated deficit			(794,309)						(799,190)
Accumulated other comprehensive loss			(621)						(382)
Treasury stock, at cost, 1,476,215 and 1,355,169 shares as of July 31, 2026 and January 31, 2026, respectively			(46,629)						(45,520)
Total Stockholders’ Equity			371,851						337,207
Total Liabilities and Stockholders’ Equity			$	646,977					$	663,790

Phreesia, Inc.

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share data)

			Three months ended July 31,												Six months ended July 31,
			2026						2025						2026						2025
Revenue:
Subscription and related services			$	52,695					$	53,702					$	105,416					$	108,057
Payment solutions(1)			38,489						28,392						80,430						58,317
Network solutions			38,274						35,161						74,547						66,817
Total revenues			129,458						117,255						260,393						233,191
Expenses:
Cost of revenue (excluding depreciation and amortization)			19,271						17,398						36,930						34,035
Payment solutions expense(1)			23,914						20,243						49,589						41,671
Sales and marketing			24,587						25,396						48,796						51,439
Research and development			27,571						29,274						55,899						61,103
General and administrative			16,512						19,042						34,873						35,450
Depreciation			3,340						3,279						6,711						6,265
Amortization			6,655						4,130						13,238						8,022
Total expenses			121,850						118,762						246,036						237,985
Operating income (loss)			7,608						(1,507)						14,357						(4,794)
Other (expense) income, net			(2,888)						336						(2,895)						674
Loss on extinguishment of debt			—						—						(17)						—
Interest expense			(1,729)						(391)						(4,028)						(826)
Interest income			248						999						545						1,204
Total other (expense) income, net			(4,369)						944						(6,395)						1,052
Income (loss) before income tax expense			3,239						(563)						7,962						(3,742)
Income tax (expense) benefit			(1,321)						1,217						(3,081)						482
Net income (loss)			$	1,918					$	654					$	4,881					$	(3,260)
Net income (loss) per share attributable to common stockholders:
Basic			$	0.03					$	0.01					$	0.08					$	(0.06)
Diluted			$	0.03					$	0.01					$	0.08					$	(0.06)
Weighted-average common shares outstanding:
Basic			61,878,316						59,591,545						61,419,374						59,261,722
Diluted			62,463,449						61,685,811						62,259,892						59,261,722
(1) Beginning with the fourth quarter of the fiscal year ended January 31, 2026, the revenue line previously labeled “Payment processing fees” was relabeled “Payment solutions” to reflect the expanded scope of our payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. “Payment solutions” includes all revenue previously presented as “Payment processing fees” and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, “Payment processing expense” was relabeled “Payment solutions expense” and includes all expenses previously presented as “Payment processing expense” and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts.

Phreesia, Inc.

Unaudited Consolidated Statements of Comprehensive Income (Loss)

(in thousands)

			Three months ended July 31,												Six months ended July 31,
			2026						2025						2026						2025
Net income (loss)			$	1,918					$	654					$	4,881					$	(3,260)
Other comprehensive (loss) income:
Net change in unrealized (loss) gain on cash flow hedges			(37)						(199)						(118)						208
Change in foreign currency translation adjustments			(13)						(73)						(121)						(45)
Other comprehensive (loss) income			(50)						(272)						(239)						163
Comprehensive income (loss)			$	1,868					$	382					$	4,642					$	(3,097)

Phreesia, Inc.

Unaudited Consolidated Statements of Cash Flows

(in thousands)

			Three months ended July 31,												Six months ended July 31,
			2026						2025						2026						2025
Operating activities:
Net income (loss)			$	1,918					$	654					$	4,881					$	(3,260)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization			9,995						7,409						19,949						14,287
Stock-based compensation expense			11,875						16,230						25,429						33,455
Amortization of deferred financing costs			132						62						566						124
Loss on extinguishment of debt			—						—						17						—
Cost of Phreesia hardware purchased by customers			245						157						433						593
Deferred contract acquisition costs amortization			108						242						224						352
Non-cash operating lease expense			564						218						797						433
Deferred taxes			1,136						(1,583)						1,813						(1,498)
Gains and losses for fair value option			2,812						—						2,812						—
Changes in operating assets and liabilities:
Accounts receivable			185						(1,820)						7,916						(3,310)
Cash received for sale of receivables			995						—						8,706						—
Accrued interest receivable			(12)						—						117						—
Prepaid expenses and other assets			(2,640)						(2,660)						(1,812)						(2,916)
Deferred contract acquisition costs			—						(351)						—						(351)
Accounts payable			489						2,068						648						329
Accrued expenses and other liabilities			4,982						(1,289)						(2,003)						(2,180)
Payment of due to provider for receivables sold to securitization			(8,480)						—						(13,540)						—
Lease liabilities			(452)						(238)						(862)						(490)
Deferred revenue			(5,524)						(4,264)						(13,841)						(5,883)
Net cash provided by operating activities			18,328						14,835						42,250						29,685
Investing activities:
Collections of cardholder receivables held for investment and deferred purchase price			26,672						—						39,024						—
Capitalized internal-use software			(4,012)						(3,435)						(7,252)						(7,323)
Purchases of property and equipment			(492)						(1,767)						(4,802)						(5,271)
Net cash provided by (used in) investing activities			22,168						(5,202)						26,970						(12,594)
Financing activities:
Proceeds from issuance of common stock upon exercise of stock options			10						114						141						242
Treasury stock to satisfy tax withholdings on stock compensation awards			(14)						—						(1,109)						—
Proceeds from employee stock purchase plan			236						575						758						1,343
Finance lease payments			(1,188)						(2,510)						(2,868)						(3,886)
Principal payments on financing agreements			(364)						(328)						(719)						(648)
Debt issuance costs and loan facility fee payments			—						—						(2,259)						(38)
Debt extinguishment costs			—						—						(42)						—
Proceeds from debt instruments			—						—						92,240						—
Principal payments on debt instruments			(23,500)						—						(121,500)						—
Payments due to provider for unfunded receivables			(17,462)						—						(33,017)						—
Net cash used in financing activities			(42,282)						(2,149)						(68,375)						(2,987)
Effect of exchange rate changes on cash, cash equivalents and restricted cash			25						(89)						(39)						(58)

Net (decrease) increase in cash, cash equivalents and restricted cash			(1,761)						7,395						806						14,046
Cash, cash equivalents and restricted cash – beginning of period			76,397						90,871						73,830						84,220
Cash, cash equivalents and restricted cash – end of period			$	74,636					$	98,266					$	74,636					$	98,266
Supplemental information of non-cash investing and financing information:
Non-cash activity related to credit card receivables and deferred purchase price			$	20,992					$	—					$	48,709					$	—
Exchange of right of use asset for property and equipment			$	—					$	—					$	57					$	—
Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities			$	2,140					$	2,461					$	2,140					$	2,461
Capitalized stock-based compensation			$	238					$	320					$	580					$	652
Issuance of stock to settle liabilities for stock-based compensation			$	919					$	1,346					$	8,972					$	7,854
Cash paid for:
Interest			$	703					$	330					$	4,551					$	654
Income taxes			$	2,884					$	763					$	4,065					$	1,314
Reconciliation of cash, cash equivalents and restricted cash shown in statements of cash flows
Cash, cash equivalents and restricted cash per balance sheets			$	72,945					$	98,266					$	72,945					$	98,266
Restricted cash included in other long-term assets			1,691						—						1,691						—
Total cash, cash equivalents and restricted cash shown in statements of cash flows			$	74,636					$	98,266					$	74,636					$	98,266

Non-GAAP Financial Measures

This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules.

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income (loss) before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in the three months ended October 31, 2025 to include an adjustment for acquisition-related costs, which consist primarily of legal, advisory and other professional fees and integration costs related to acquisitions. Management believes adjusting for these acquisition-related costs provides investors with a more consistent period-to-period comparison of our core operating performance and trends. For periods prior to the three and nine months ended October 31, 2025, the calculation of Adjusted EBITDA did not adjust for acquisition-related costs, and prior periods have not been retroactively adjusted.

We have provided below a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Quarterly Report on Form 10-Q to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other expense (income), net and income tax expense (benefit) which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss).

Our use of Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

•Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;

•Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; (4) loss on extinguishment of debt; (5) interest expense; (6) interest income; (7) other expense (income), net; or (8) certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs; and

•Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net income (loss), and our GAAP financial results.

The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for each of the periods indicated:

Phreesia, Inc.

Adjusted EBITDA

			Three months ended July 31,												Six months ended July 31,
(in thousands, unaudited)			2026						2025						2026						2025
Net income (loss)			$	1,918					$	654					$	4,881					$	(3,260)
Interest expense			1,729						391						4,028						826
Interest income			(248)						(999)						(545)						(1,204)
Income tax expense (benefit)			1,321						(1,217)						3,081						(482)
Depreciation and amortization			9,995						7,409						19,949						14,287
Stock-based compensation expense			11,875						16,230						25,429						33,455
Loss on extinguishment of debt			—						—						17						—
Other expense (income), net			2,888						(336)						2,895						(674)
Other items affecting comparability(1)			3,442						—						3,659						—
Adjusted EBITDA			$	32,920					$	22,132					$	63,394					$	42,948
(1) For the three months ended July 31, 2026, other items affecting comparability consisted of $0.7 million of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition and $2.8 million of severance, taxes and employee benefit costs associated with the restructuring plan. For the six months ended July 31, 2026, other items affecting comparability consisted of $0.9 million of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition and $2.8 million of severance, taxes and employee benefit costs associated with the restructuring plan.

We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment.

Additionally, free cash flow is a supplemental measure of our liquidity that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position.

The following table presents a reconciliation of free cash flow to net cash provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated:

Phreesia, Inc.

Free cash flow

			Three months ended July 31,												Six months ended July 31,
(in thousands, unaudited)			2026						2025						2026						2025
Net cash provided by operating activities			$	18,328					$	14,835					$	42,250					$	29,685
Less:
Capitalized internal-use software development costs			(4,012)						(3,435)						(7,252)						(7,323)
Purchases of property and equipment			(492)						(1,767)						(4,802)						(5,271)
Free cash flow			$	13,824					$	9,633					$	30,196					$	17,091

Phreesia, Inc.

Supplementary Information

(Unaudited)

			Three months ended July 31,												Six months ended July 31,
(in thousands)			2026						2025						2026						2025
GAAP operating expenses
General and administrative			$	16,512					$	19,042					$	34,873					$	35,450
Sales and marketing			24,587						25,396						48,796						51,439
Research and development			27,571						29,274						55,899						61,103
Cost of revenue (excluding depreciation and amortization)			19,271						17,398						36,930						34,035
			$	87,941					$	91,110					$	176,498					$	182,027
Stock compensation included in GAAP operating expenses
General and administrative			$	5,392					$	6,362					$	10,881					$	12,935
Sales and marketing			3,792						4,745						7,694						9,919
Research and development			2,205						4,204						5,770						8,597
Cost of revenue (excluding depreciation and amortization)			486						919						1,084						2,004
			$	11,875					$	16,230					$	25,429					$	33,455
Other items affecting comparability included in GAAP operating expenses
General and administrative			$	848					$	—					$	1,065					$	—
Sales and marketing			300						—						300						—
Research and development			2,022						—						2,022						—
Cost of revenue (excluding depreciation and amortization)			272						—						272						—

Phreesia, Inc.
Key Metrics
(Unaudited)

			Three months ended July 31,												Six months ended July 31,
			2026						2025						2026						2025
Average number of healthcare services clients ("AHSCs")			4,744						4,467						4,726						4,439
Total revenue per AHSC			$	27,289					$	26,249					$	55,098					$	52,532

The definitions of our key metrics are presented below.

•AHSCs. We define AHSCs as the average number of clients that generate subscription and related services or payment solutions revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single healthcare services client. We believe growth in AHSCs is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our solutions to healthcare services organizations that are not yet clients. We believe growth in AHSCs provides useful information to investors as an important indicator of expected revenue growth. In addition, growth in AHSCs informs our management of the areas of our business that will require further investment to support expected future AHSC growth. For example, as AHSCs increase, we may need to add to our customer support team and invest to maintain effectiveness and performance of our solutions for our healthcare services clients and their patients.

•Total revenue per AHSC. We define total revenue per AHSC as total revenue in a given period divided by the number of AHSCs during that same period. Our healthcare services clients directly generate subscription and related services and payment solutions revenue. Additionally, our relationships with healthcare services clients who subscribe to our solutions give us the opportunity to engage with life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations who deliver direct communication to patients through our solutions. As a result, we believe that our ability to increase total revenue per AHSC provides useful information to investors as an indicator of the long-term value of our solutions.

Phreesia, Inc.

Additional Information

(Unaudited)

			Three months ended												Six months ended
			July 31, 2026						January 31, 2026(1)						July 31, 2026						January 31, 2026(1)
Total managed payments (in billions)			$	1.626					$	1.560					$	3.412					$	3.194
Payment solutions revenue rate			2.4		%				2.3		%				2.4		%				2.0		%
(1) The AccessOne Acquisition was completed on November 12, 2025. Reflects inclusion of the business operations of AccessOne from November 12, 2025 to January 31, 2026 and therefore the payment solutions revenue rate for the three and six months ended January 31, 2026 is not indicative of AccessOne’s full performance for the periods presented.

Total managed payments and payment solutions revenue rate were introduced in the first quarter of fiscal 2027. We believe these metrics will enable investors to better evaluate the performance of our payment solutions business following the AccessOne Acquisition during the fourth quarter of fiscal 2026, which introduced new revenue-generating activities. These metrics have replaced patient payment volume and payment facilitator volume percentage, which reflected only the legacy Phreesia payment processing business4. Total managed payments reflects both the transactional activity we facilitate and the financing solutions we provide to healthcare organizations and patients. These metrics provide a clear and consistent framework for understanding how payment activity translates into revenue, enabling investors to more effectively assess the growth, performance and overall value of our payment solutions business.

•Total managed payments. We define total managed payments as the sum of (i) our legacy patient payment volume, measured as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator, as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors; and (ii) the average month-end outstanding balance of our managed portfolio of cardholder receivables, calculated as the average of all month-end balances during the applicable period. We believe total managed payments are a useful indicator of the scale and health of our payments ecosystem, reflecting both the volume of transactions we facilitate and the size of the receivables portfolio we service. Total managed payments are one of the primary drivers of our total payments revenue.

•Payment solutions revenue rate. We define our payment solutions revenue rate as total payment solutions revenue divided by total managed payments for a given period. This rate reflects the combined monetization of both our payment processing and patient financing activities into a single, unified rate. We believe this metric provides a useful lens into the efficiency and stability of our revenue model over time, enabling investors to better understand how changes in volume and portfolio size translate into revenue and to more easily evaluate the underlying performance and scalability of our payment solutions business. Because total managed payments includes both transaction volume and average receivables balances, payment solutions revenue rate should not be interpreted as a processing take rate, interest yield or margin.

4 For periods prior to the three months ended April 30, 2026, we presented (i) patient payment volume (measured as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors) and (ii) payment facilitator volume percentage (defined as the volume of credit and debit card patient payments that we process as a payment facilitator as a percentage of total patient payment volume).

Quarterly Stakeholder Letter SECOND QUARTER | FISCAL YEAR 2027

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 2 Dear Phreesia stakeholders, Phreesia delivered a solid fiscal second quarter, with revenue growth and profitability expansion in line with our expectations. We generated positive operating and free cash flow again this quarter, which together with available cash allowed us to reduce debt principal by over $23 million while maintaining a healthy cash balance. We remain enthusiastic about two products that we believe will drive future growth, AccessOne and ProviderConnect, as well as the impact that our artificial intelligence (AI) investments are beginning to have on many aspects of our products and broader organization. During the quarter, our team built momentum with existing clients around the AccessOne offering while continuing to invest in product enhancements and integrations across the broader Phreesia platform. ProviderConnect, our Network Solutions offering that launched earlier this year, is also seeing a strong response in the market as a differentiated way for life sciences companies to engage the right providers at the right time. We are excited about the opportunity for both offerings to enhance client value and accelerate revenue growth as we expand their reach across existing and new markets. At the same time, newer offerings such as PlanMatch and VoiceAI are creating additional opportunities to bring value to existing and new clients. As clients adopt more of these offerings, we believe Phreesia will become more embedded in their day-to-day workflows and strengthen the overall value our platform brings to providers. AI is playing an increasingly important role across this work. We are applying AI to reduce manual work for our clients, surface the right information at the right moment and continuously improve through real- world use, from intake and eligibility to clinical workflows and beyond. Together AccessOne, ProviderConnect, PlanMatch and VoiceAI reflect how we are increasingly thinking about Phreesia: as a way to add value at the moment of the visit itself — the single touchpoint where subscription, payments and network solutions all meet. With over 180 million patient visits flowing through Phreesia in 2025, roughly one in six across the U.S., we believe improvements like these can compound meaningfully across our network. I am proud of our team’s commitment to our mission and values, and I look forward to updating you further as fiscal 2027 progresses. SEPTEMBER 2, 2026 Chaim Indig Chief Executive Officer and Co-Founder

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 3 Fiscal 2027 Second Quarter Highlights1 In the second quarter of fiscal 2027, total revenue increased 10% year-over-year to $129.5 million, once again led by payment solutions2, which grew 36%, largely driven by the contribution from AccessOne. As a reminder, given the seasonality in our payment processing business associated with reset of health plan deductibles, payment processing revenue is typically highest during the first fiscal quarter of each year. Network solutions revenue grew 9% year-over-year, while subscription and related services revenue declined 2%, consistent with our deliberate move to moderate subscription pricing in favor of downstream payment and network solutions growth, as we have noted in recent quarters. In the second quarter of fiscal 2027, we supported 4,744 Average Healthcare Services Clients (AHSCs)³, an increase of 36 AHSCs (or 1%) over the first quarter of fiscal 2027 and an increase of 277 AHSCs (or 6%) year-over-year, consistent with our expectations. Total revenue per AHSC⁴ was $27,289, up 4% year-over-year. On a sequential basis, total revenue per AHSC declined approximately 2%, reflecting the payment processing seasonality described above along with continued growth in our client base. ¹ The fiscal quarter that ended July 31, 2026 should be considered “unaudited.” For additional financial information regarding the fiscal quarter ended July 31, 2026, refer to our quarterly earnings release filed with the Securities and Exchange Commission (“SEC”) on September 2, 2026. 2 Beginning with the fourth quarter of the fiscal year ended January 31, 2026, the revenue line previously labeled “Payment processing fees” was relabeled “Payment solutions” to reflect the expanded scope of our payments offerings following the acquisition (the “AccessOne Acquisition”) of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, “AccessOne”), which closed on November 12, 2025. “Payment solutions” includes all revenue previously presented as “Payment processing fees” and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, “Payment processing expense” was relabeled “Payment solutions expense” and includes all expenses previously presented as “Payment processing expense” and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts. 3 We define AHSCs as the average number of clients that generate subscription and related services or payment solutions revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partners’ clients, we treat the contractual relationship as a single healthcare services client. 4 We define total revenue per AHSC as total revenue in a given period divided by the number of AHSCs during that same period.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 4 Revenue growth exceeded expense growth, continuing the operating leverage we've built over the past two years: cost of revenue and payment solutions expense grew modestly alongside higher payment and patient financing volumes, while sales & marketing, research & development, and general & administrative expense each declined year-over-year. Net income was $1.9 million in the second quarter of fiscal 2027, up from net income of $0.7 million in the second quarter of fiscal 2026. Adjusted EBITDA5 was $32.9 million in the second quarter of fiscal 2027, up from $22.1 million in the second quarter of fiscal 2026. Total Revenue Per AHSC¹ (Q3 FY2025 - Q2 FY20272) 1 Calculations for each period are presented as total revenue for that period divided by the number of AHSCs during the same period. Total revenue per AHSC may not sum to annual results due to rounding. 2 Fiscal year ended January 31. 5 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net (loss) income before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. See “Non-GAAP Financial Measures” for more information and a reconciliation of Adjusted EBITDA to the closest GAAP measure.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 5 We encourage readers to refer to the accompanying charts, our earnings press release and our Form 10-Q for additional detail on the quarter's financial results. Operating Expense Trends ($M, Q3 FY2025 - Q2 FY20271) 1 Fiscal year ended January 31. 2 Subscription & network solutions cost as a percentage of revenue equals cost of revenue (excluding depreciation and amortization), divided by the sum of subscription and related services revenues and network solutions revenues, each per our unaudited consolidated statements of operations for the periods presented. 3 Payment solutions expense as a percentage of revenue equals payment solutions expense divided by payment solutions revenues, each per our unaudited consolidated statements of operations for the periods presented.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 6 Payment Solutions Statistics Total managed payments⁶ and payment solutions revenue rate7 were introduced in the first quarter of fiscal 2027. Total managed payments reflects both the transactional activity we facilitate and the financing solutions we provide to healthcare organizations and patients. Payment solutions revenue rate reflects the combined monetization of both our payment processing and patient financing activities into a single, unified rate. We believe these metrics provide a clear and consistent framework for understanding how payment activity translates into revenue, enabling investors to more effectively assess the growth, performance and overall value of our payment solutions business. In the second quarter of fiscal 2027, our total managed payments were $1.626 billion and our payment solutions revenue rate was 2.4%. The following chart shows total managed payments and payment solutions revenue rate for the fiscal fourth quarter of 20268, the fiscal first quarter of 2027 and the fiscal second quarter of 2027. 6 We define total managed payments as the sum of: i) our legacy patient payment volume, measured as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator, as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors; and ii) the average month-end outstanding balance of our managed portfolio of cardholder receivables, calculated as the average of all month-end balances during the applicable period. 7 We define our payment solutions revenue rate as total payment solutions revenue divided by total managed payments for a given period. Because total managed payments include both transaction volume and average receivables balances, the payment solutions revenue rate should not be interpreted as a processing take rate, interest yield or margin. 8 The AccessOne Acquisition was completed on November 12, 2025. The quarter ended January 31, 2026 reflects inclusion of the business operations of AccessOne from November 12, 2025 to January 31, 2026, and therefore, the payment solutions revenue rate for the three months ended January 31, 2026 is not indicative of AccessOne’s full-quarter performance.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 7 Payment Solutions Statistics ($B, Q4 FY2026 - Q2 FY20271) 1 Fiscal year ended January 31. 2 We define total managed payments as the sum of: 1) our legacy patient payment volume, measured as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator, as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors; and 2) the average month-end outstanding balance of our managed portfolio of cardholder receivables, calculated as the average of all month-end balances during the applicable period. We believe total managed payments are a useful indicator of the scale and health of our payments ecosystem, reflecting both the volume of transactions we facilitate and the size of the receivables portfolio we service. Total managed payments are one of the primary drivers of our total payments revenue. 3 We define our payment solutions revenue rate as total payment solutions revenue divided by total managed payments for a given period. This rate reflects the combined monetization of both our payment processing and patient financing activities into a single, unified rate. We believe this metric provides a useful lens into the efficiency and stability of our revenue model over time, enabling investors to better understand how changes in volume and portfolio size translate into revenue and to more easily evaluate the underlying performance and scalability of our payment solutions business. Because total managed payments includes both transaction volume and average receivables balances, the payment solutions revenue rate should not be interpreted as a processing take rate, interest yield or margin. 4 The AccessOne Acquisition was completed on November 12, 2025. The quarter ended January 31, 2026 reflects inclusion of the business operations of AccessOne from November 12, 2025 to January 31, 2026, and therefore, the payment solutions revenue rate for the three months ended January 31, 2026 is not indicative of AccessOne’s full-quarter performance.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 8 9 References to net cash provided by operating activities and free cash flow throughout this letter relate to the cash flow categories in our consolidated statements of cash flows and free cash flow reconciliation within Part I - Item 1 and 2 of our Quarterly Report on Form 10-Q. 10 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See the “Non-GAAP Financial Measures” section of this letter for a reconciliation of free cash flow to the closest GAAP measure. In the second quarter of fiscal 2027, net cash provided by operating activities⁹ was $18.3 million, an increase of $3.5 million year-over-year, as compared to $14.8 million in the second quarter of fiscal 2026. In the second quarter of fiscal 2027, we generated free cash flow10 of $13.8 million, an increase of $4.2 million year-over-year, as compared to $9.6 million in the second quarter of fiscal 2026. We utilized free cash flow and available cash to reduce our long-term debt by $23.5 million during the second quarter of fiscal 2027, with $60.7 million of long term debt as of July 31, 2026. As of July 31, 2026 and January 31, 2026, we had cash, cash equivalents and restricted cash of $74.6 million and $73.8 million, respectively.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 9 Phreesia Solutions Our broad capabilities bring value to patients, providers and life sciences companies in unique ways.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 10 Access Expanding Eligibility and Benefits Beyond Verification Eligibility and benefits (E&B) verification is an important part of patient registration, but confirming eligibility status is only the beginning. Front desk staff still need to make sure the right insurance is on file, understand what the eligibility response means, consider any conditions and select the correct billing plan in the practice management (PM) system. Those manual steps are time- consuming and create opportunities for error that can lead to claim denials and delayed reimbursement. One of our clients recently reported that nearly 80% of its registration-related denials stemmed from incorrect insurance or plan selection. Over the past year, we have continued expanding our E&B capabilities to simplify this process for both patients and providers. Patients can now upload insurance cards during intake, where optical character recognition (OCR) can extract key insurance details, reducing manual entry while making check-in easier. We have also expanded eligibility verification to support up to three insurance plans per patient, automatically identify vision, medical and dental coverage to support accurate insurance assignment, and begin verification 30 days before an appointment, helping identify and resolve coverage issues before the day of care. Building on these capabilities, we recently introduced PlanMatch, our new AI-powered E&B solution built to put artificial intelligence to work at one of the most error-prone steps in patient registration: selecting the right billing plan. Because the Phreesia platform already connects the patient, the payer and the PM system before the visit, PlanMatch is able to compare and reconcile information across all three in real time to identify the billing plan that best matches a patient's coverage. On average, staff must choose from eight possible billing plans during scheduling, making the process both time-consuming and complex. PlanMatch automatically compares the patient's live eligibility response with each organization's unique billing plan structure and learns how that organization maps payer responses to its billing plans, allowing it to recommend the correct plan before check-in, when there is still time to resolve issues. Those recommendations are automatically surfaced in the Phreesia

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 11 system for staff to review, reducing manual work and improving billing accuracy. As staff confirm or adjust those recommendations, PlanMatch's underlying AI learns from those decisions, allowing it to handle increasingly complex scenarios and become more accurate the longer it's in use. Early results from beta clients are encouraging. Within two months, one 70-location multispecialty medical group saw: 95% staff acceptance of PlanMatch recommendations PlanMatch make billing recommendations for 99% of patients Affordability and Cash Flow Metroplex Medical Centres: Strengthening Financial Performance Metroplex Medical Centres, a nine-location primary care organization in Texas, is one example of how our clients are realizing more value from the Phreesia platform. Working closely with our teams to optimize existing workflows following an onsite visit, Metroplex achieved measurable improvements across collections, operational efficiency and patient access over the course of 10 months. Key outcomes included: $2 million collected through Phreesia, representing approximately $1.2 million in annualized value from reallocated staff time and wages $60,000 in overdue patient balances collected within 90 days after implementing and optimizing Patient Bill Pay More than $442,000 in cost savings in just four months through workflow improvements and automation with VoiceAI 3x increase in self-scheduled visits We believe these results demonstrate the value providers can unlock by optimizing and expanding their use of the Phreesia platform. Metroplex's experience reflects a broader dynamic we're watching closely: as patients carry a growing share of the cost of every visit, providers are looking for financing and collections tools that keep that process humane and predictable for both sides.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 12 Health Outcomes Phreesia and March of Dimes Partner to Help Improve Maternal and Infant Health Phreesia and March of Dimes, the nation's leading nonprofit fighting for the health of all moms and babies, recently announced a partnership designed to enhance physician-patient conversations during prenatal and postpartum appointments. Through the collaboration, the organizations will reach new parents, caregivers of infants and their healthcare providers with timely, evidence- based education ahead of relevant appointments, with the goal of improving the health of mothers and babies across the United States. The campaign brings March of Dimes' educational content to clinically relevant patients, along with complementary resources for providers caring for pregnant patients and caregivers of infants. With the goal of improving maternal and infant health outcomes, Phreesia and March of Dimes aim to raise awareness of three important issues: preeclampsia, postpartum depression and safe sleep practices for infants. "Every mom deserves access to trusted, timely information that helps them have meaningful conversations with their provider and make informed decisions throughout their pregnancy, birth and postpartum," said Kelly Ernst, Chief Impact Officer, March of Dimes. "However, it can be challenging to know what questions to ask and when during the pregnancy journey. We're proud to partner with Phreesia to share evidence-based resources ahead of key appointments to strengthen those conversations, helping improve the health of moms and babies." Leveraging both PatientConnect and ProviderConnect in tandem, the campaign closes the loop between patients and HCPs. By delivering both patient education and provider resources to relevant audiences just before appointments, the campaign aims to support better shared decision-making and improved outcomes. Helping Families Learn About RSV Prevention Last year, Phreesia partnered with Sanofi on a PatientConnect campaign to educate expectant parents and caregivers of infants about respiratory syncytial virus (RSV) and prevention options before healthcare appointments. Delivering evidence-based education to 1.9 million caregivers during check-in, the six-month campaign helped families prepare for more informed conversations with their providers at the moment healthcare decisions were being made.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 13 A third-party analysis found that babies whose caregivers were exposed to the campaign were significantly more likely to receive preventive treatment for RSV than a matched control group. Results include: 64% of caregivers who saw the campaign reported they were very likely to ask their doctor about preventive treatment for RSV, nearly 2x the Phreesia benchmark for similar campaigns 21,500+ incremental treatments for RSV were administered as a result of this campaign Patients whose caregiver saw the campaign were 15x more likely to receive preventive treatment for RSV than a matched control group 83% of conversions occurred within 3 months of campaign exposure, including 13% on the day caregivers saw the campaign We believe these results demonstrate how delivering trusted health education at the point of care can help new parents make more informed healthcare decisions, support conversations with providers and drive measurable value for our life sciences partners. Helping More Patients Start Treatment Through ProviderConnect As new dosing options entered the GLP-1 market, a cardiometabolic brand sought to educate a broad group of providers across specialties about these new treatment options. Reaching providers when those treatment conversations were most relevant was an important part of that effort. Using our scheduling signals, ProviderConnect engaged providers seeing relevant patients around the time of their appointments, connecting the education more closely to when treatment decisions were being discussed. A four-month test-vs-control study measured the impact of the campaign among providers seeing patients eligible for GLP-1 treatment. Campaign results include: More than 380,000 patients discussed treatments with their provider A 4% incremental lift in new-to- brand prescriptions versus a matched control group More than 1,000 new patient starts versus a matched control group Over 6,900 providers received messaging ahead of an appointment These results highlight that reaching providers based on real-world care signals, real scheduling data and patient-level relevance can help more patients start treatment. We continue to invest in ProviderConnect as we aim to expand its adoption across our network solutions client base.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 14 New Research Highlights the Important Role of Provider Conversations in GLP-1 Treatment Decisions Earlier this year, we conducted a PatientInsights study to understand the shifting landscape around GLP-1 treatments among adults diagnosed with type 2 diabetes or overweight, with and without a history of GLP-1 treatment. Where patients first learn about GLP-1s is closely tied to whether they ultimately begin treatment, and the doctor’s office often plays an important role in learning about these therapies. Among patients with type 2 diabetes who had tried a GLP-1, 64% first heard about the therapy from their healthcare provider, compared with just 8% of those who had never tried one. Patients seeking treatment for obesity showed a similar pattern. Conversely, the research also found that many patients who could benefit from GLP-1 therapy never discuss it with their provider. Among patients with type 2 diabetes who had not started treatment, the two most common barriers were that their provider had not recommended a GLP-1 or had never discussed one at all; surprisingly, ranking ahead of cost and side effects. In contrast, patients who frequently discussed GLP-1 therapy with their provider reported greater confidence in treatment, higher satisfaction and approximately half the discontinuation rate of those who rarely had those conversations. These findings reinforce that the point of care remains one of the most important moments for patients as they make treatment decisions. Our platform helps reach both patients and providers before those conversations take place, helping to enable more informed conversations and improve health outcomes. Business and Financial Outlook We are maintaining our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million. As we noted over the past several quarters, there is now more variability in our network solutions revenue forecasting, particularly in the second half of each fiscal year. Our visibility into revenue across the other parts of our business is generally consistent with our views in our March 2026 earnings disclosure. The revenue range provided for fiscal 2027 assumes approximately $37 million of contributions from AccessOne and no additional revenue from potential future acquisitions completed between now and January 31, 2027. We are maintaining our Adjusted EBITDA outlook for fiscal 2027. We expect Adjusted EBITDA to be in the range of $125 million to $135 million. As a reminder, in May 2026, we implemented a restructuring plan intended to reduce operating expenses and better align our cost structure with our current business priorities. The plan is expected to result in meaningful annualized run-rate expense savings, which were reflected in our Adjusted EBITDA outlook provided on March 30, 2026 and reaffirmed on May 27, 2026. We are maintaining our expectation for AHSC growth in the mid-single-digit percentage range, and we are maintaining our outlook for total revenue per AHSC to grow in the low-single-digit percentage range for fiscal 2027.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 15 About Phreesia Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025 — 1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com. Investor contact: Balaji Gandhi investors@phreesia.com Media contact: Nicole Gist nicole.gist@phreesia.com Non-GAAP Financial Measures This stakeholder letter and statements made during the webcast referenced below may include certain non-GAAP financial measures as defined by SEC rules. Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net (loss) income before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in the three months ended October 31, 2025 to include an adjustment for acquisition-related costs, which consist primarily of legal, advisory and other professional fees and integration costs related to acquisitions. Management believes that adjusting for these acquisition-related costs provides investors with a more consistent period-to-period comparison of

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 16 our core operating performance and trends. For periods prior to the three months ended October 31, 2025, the calculation of Adjusted EBITDA did not adjust for acquisition-related costs, and prior periods have not been retroactively adjusted. We have provided below a reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable GAAP financial measure. We have also presented Adjusted EBITDA in the press release accompanying this letter and in our Quarterly Report on Form 10-Q to be filed after this letter because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. We have not reconciled our Adjusted EBITDA outlook to GAAP net (loss) income because we do not provide an outlook for GAAP net (loss) income due to the uncertainty and potential variability of other expense (income), net, income tax expense (benefit), which are reconciling items between Adjusted EBITDA and GAAP net (loss) income. Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net (loss) income. Our use of Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows: • Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; • Adjusted EBITDA does not reflect: 1) changes in, or cash requirements for, our working capital needs; 2) the potentially dilutive impact of non-cash stock-based compensation; 3) tax payments that may represent a reduction in cash available to us; 4) loss on extinguishment of debt; 5) interest expense; 6) interest income; 7) other expense (income), net; or 8) certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs; and • Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 17 Because of these and other limitations, Adjusted EBITDA should be considered along with other GAAP- based financial performance measures, including various cash flow metrics, net (loss) income and our GAAP financial results. $M Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Net (loss) income $(14.4) $(6.4) $(3.9) $0.7 $4.3 $1.3 $3.0 $1.9 Interest expense 0.6 0.6 0.4 0.4 0.3 5.8 2.3 1.7 Interest income (0.6) (0.6) (0.2) (1.0) (0.7) (0.3) (0.3) (0.2) Income tax expense (benefit) 0.4 1.0 0.7 (1.2) 0.9 (11.6) 1.8 1.3 Depreciation and amortization 7.1 6.8 6.9 7.4 7.5 9.7 10.0 10.0 Stock-based compensation expense 16.5 17.2 17.2 16.2 16.0 18.0 13.6 11.9 Loss on extinguishment of debt – – – – – 0.5 – – Other expense (income), net 0.1 (2.2) (0.3) (0.3) (1.0) (1.3) – 2.9 Other items affecting comparability1 – – – – 2.0 7.3 0.2 3.4 Adjusted EBITDA2,3 $9.8 $16.4 $20.8 $22.1 $29.1 $29.4 $30.5 $32.9 1 For the three months ended October 31, 2025, January 31, 2026 and April 30, 2026, other items affecting comparability consisted of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition. For the three months ended July 31, 2026, other items affecting comparability consisted of $0.7 million of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition and $2.8 million of severance, taxes and employee benefit costs associated with the restructuring plan. 2 We calculate Adjusted EBITDA as net (loss) income before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. 3 May not foot due to rounding. We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. Additionally, free cash flow is a supplemental measure of our liquidity that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 18 The following table presents a reconciliation of free cash flow to net cash provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated: $M Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Net cash provided by operating activities $5.8 $16.3 $14.9 $14.8 $15.5 $33.7 $23.9 $18.3 Less: Capitalized internal-use software development costs (3.6) (4.3) (3.9) (3.4) (3.4) (2.6) (3.2) (4.0) Purchases of property and equipment (0.6) (2.8) (3.5) (1.8) (3.3) (2.6) (4.3) (0.5) Free Cash Flow1,2 $1.6 $9.2 $7.5 $9.6 $8.8 $28.5 $16.4 $13.8 Forward-Looking Statements This stakeholder letter includes express or implied statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, Adjusted EBITDA and cash flows; our expectations regarding demand for our solutions and visibility into future revenue; our expectations regarding our restructuring plan, reductions in operating expenses and resulting expense savings; the expected results of the AccessOne Acquisition discussed herein, including anticipated additional revenue; our estimated addressable market; our outlook for fiscal 2027, including with respect to revenue, Adjusted EBITDA and our expectations on AHSCs, total revenue per AHSC, and our plans to achieve our revenue and Adjusted EBITDA targets in fiscal 2027; our ability to continue generating positive net income and free cash flow; our expectation for subscription growth to be slower than payment solutions and network 1 We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. Additionally, free cash flow is a supplemental measure of our liquidity that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position. 2 May not foot due to rounding.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 19 solutions growth and our strategy to optimize client adoption and retention; our business strategy and operating plans; industry trends and predictions; our anticipated growth and operating leverage; the factors that drive our revenue growth; our expectations regarding new solutions and solutions under development and the use of AI in our solutions; our growth expectations and strategies for the AccessOne business and ProviderConnect; our ability to offer the AccessOne solution to additional clients; our expectations regarding the growth of our network of clients and partners and adoption of our solutions; our expectations regarding the impact of AI across our products and broader oraganization. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the competitive environment in which we operate; our ability to comply with the covenants in our credit facility with Capital One and the securitization program with PNC Bank; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general, market, political, economic and business conditions (including from the U.S. federal government, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this letter are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission (“SEC”), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026 that will be filed with the SEC after this letter. The forward-looking statements in this letter speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this letter to reflect events or circumstances after the date of this letter or to reflect new information or the occurrence of unanticipated events, except as required by law.

QUARTERLY STAKEHOLDER LETTER | SECOND QUARTER 2027 | 20 This letter also includes statistical data, estimates and forecasts that are based on industry publications or other publicly available information, as well as other information based on our internal sources. This information may be based on many assumptions and limitations, and you are cautioned not to give undue weight to such information. We have not independently verified the accuracy or completeness of the information contained in these industry publications and other publicly available information. This letter includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above. Conference Call Information We will hold a conference call on Wednesday, September 2, 2026 at 5:00 PM ET to review our fiscal 2027 second quarter financial results. To participate in our live conference call and webcast, please dial (833) 461-5787 (or (626) 884-3620 for international participants) using conference code number 285419602 or visit the “Events & Presentations” section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 382.6 KB
• EX-99.2 EX-99.2 50.6 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.8 KB